Articles tagged with Radiation Therapy
The new software automates image capture and analysis, providing more accurate radiation beam targeting and refined patient positioning. This technology enhances the quality assurance strategy in radiation therapy, potentially reducing toxicity and improving treatment outcomes.
Women with early, low-risk hormone-driven breast cancer who receive radiotherapy after surgery have a significantly lower risk of recurrence and improved disease-free survival compared to those without radiotherapy. The study found that whole breast irradiation is effective in reducing in-breast recurrences and improving overall survival.
Radiation oncologists provide guidance on preparing for and responding to natural disasters, including creating emergency operations plans, providing patients with access to treatment plans via flash drives, and identifying alternative sources of power. The tips aim to minimize treatment delays during a disaster.
A clinical study demonstrated the safety and efficacy of high-dose stereotactic body radiotherapy (SBRT) for patients with centrally located non-small cell lung cancer. The treatment resulted in high tumor control rates, comparable to those seen in patients with peripheral tumors.
A genetic study has identified a risk factor for stroke among childhood cancer survivors who received cranial radiation therapy. Variants in the chromosomal region 5p15.33 increase the risk of stroke approximately five-fold among those treated with intermediate dose radiation.
Researchers have developed 3D organ-on-a-chip models to test the effects of different levels and types of radiation on human tissues. This technology could lead to more effective therapies with fewer side effects for cancer patients.
Two new studies highlight advances in lung cancer treatment. A multidisciplinary thoracic cancers symposium presents findings on local consolidative therapy linked to improved overall survival for patients with oligometastatic non-small cell lung cancer (NSCLC). Another study demonstrates the effectiveness of structured exposure to NSC...
A new study uses Raman spectroscopy to analyze changes in biochemical composition of tumors, enabling prediction of radiation response. The findings have the potential to reduce medical overtreatment and improve treatment plans for cancer patients.
A study published in Annals of Oncology found that one course of chemotherapy or radiotherapy after surgery does not have a long-term effect on sperm count and concentration in men with early stage testicular cancer. Sperm number and concentration recovered in all groups up to five years after treatment.
A researcher at the University of Cincinnati is using a $1.4 million VA grant to study radiation resistance in head and neck cancer. The goal is to target molecular pathways to make radiation therapy more effective, reducing side effects and improving treatment outcomes for patients.
A phase III trial found hypofractionated radiotherapy (H-RT) to have similar QOL outcomes as conventional radiotherapy (C-RT) in men with low risk prostate cancer. H-RT delivers a total dose over a shorter period, reducing treatment duration and potential side effects.
A new UCLA-led study shows that men with low- or intermediate-risk prostate cancer can safely undergo higher doses of radiation over a significantly shorter period and still have the same successful outcomes as from a much longer course of treatment. The study analyzed data from 2,142 men treated with stereotactic body radiotherapy for...
The University of Nebraska is leading a $11 million study to develop drug therapies protecting military service members from radiation exposure. The project, in collaboration with the Department of Defense, aims to identify and develop therapeutic candidates that can prevent and counteract radiation effects.
Patients with early-stage breast cancer who had a positive sentinel lymph node biopsy showed comparable 10-year recurrence and survival rates following axillary radiotherapy or axillary lymph node dissection. The study also found that axillary radiotherapy was associated with significantly less lymphedema, a common side effect of surgery.
Recent studies at SABCS 2018 highlight radiation therapy's efficacy in treating breast cancer, with trials refining treatments to provide more options for patients. Accelerated partial breast irradiation has been shown to be non-inferior to traditional whole breast irradiation.
Researchers at SLAC and Stanford are developing accelerator-based technology to reduce the side effects of cancer radiation therapy by vastly shrinking its duration. The goal is to blast cancer cells quickly, reducing the chance that radiation will hit and damage healthy tissue around tumors, making radiation therapy more precise.
Researchers found that combining surgery with post-operative low-dose radiation and hormone therapy reduces prostate cancer death risk to less than 10% for men with aggressive prostate cancer. In contrast, surgery alone increases the risk of death from prostate cancer within five years.
Researchers are testing Precision Breast IORT, which uses advanced imaging to tailor radiation treatment and potentially improve outcomes for patients with early-stage breast cancer. The study aims to evaluate the technique's effectiveness in reducing breast cancer recurrence rates and immune-dampening effects.
UCSF scientists create new animal model of glioma that captures the clinical lifecycle of brain tumors, allowing them to test strategies to prevent radiation-associated cognitive decline. They discover that temporarily suppressing a key immune system component can prevent this problem.
A new drug, IPdR, has been shown to be safe and effective in boosting radiotherapy for patients with various gastrointestinal cancers. The drug, a prodrug that converts into the active IUdR, can be taken orally and creates high levels of IUdR in the bloodstream, making cancer cells more susceptible to radiation.
Researchers used PSMA PET/CT to detect prostate cancer outside the prostate gland with higher sensitivity and specificity than standard imaging techniques. This improved accuracy enables more precisely targeted treatment, potentially increasing the chances of successful outcomes.
A new report by ESTRO highlights the need for improved access to radiotherapy in Europe, citing a quarter of patients who need treatment not receiving it. Experts recommend increased investment, better understanding, and integration into cancer care plans.
Long-term data show that whole breast radiation therapy significantly reduces the risk of local recurrence in low-risk ductal carcinoma in situ (DCIS) patients, even without additional treatment. Radiation also reduces overall cancer return by more than 70 percent.
Researchers found that targeting tumor sites with radiation or surgery after initial treatment can significantly improve overall survival time for patients. Progression-free survival and toxicity data also showed benefits, with median overall survival times of up to 41.2 months.
Researchers investigated alternative radiation therapy regimens for early-stage breast cancer patients. The trial found that fewer, larger individual doses of radiation led to similar adverse effects as conventional radiation therapy after 10 years.
A new radiation treatment approach, hippocampal-avoidance whole-brain radiotherapy with memantine, demonstrated better preservation of cognitive function compared to traditional whole-brain radiotherapy. The study found similar cancer control and overall survival outcomes for both groups.
A randomized phase III trial found that avoiding the hippocampal region during whole-brain radiotherapy significantly reduces the risk of cognitive decline. The study results have far-reaching implications for brain tumor treatment, offering a safer alternative to traditional whole-brain radiation therapy.
A new analysis of genetic data and clinical trial results suggests that African-American men may have comparatively higher cure rates when treated with radiation therapy. The study found that tumors from African-American men were more likely to have indicators of increased sensitivity to radiation, leading to improved outcomes.
A new study suggests that HPV-positive throat cancer patients benefit from chemoradiotherapy, leading to higher overall survival rates compared to cetuximab treatment. Cisplatin chemotherapy and radiotherapy proved more effective in reducing cancer recurrence and improving patient outcomes.
The SPPORT trial found that adding pelvic lymph node treatment and short-term hormone therapy to standard treatment extends time before cancer spreads. This combination therapy resulted in higher freedom-from-progression rates and lower distant metastasis rates compared to standard treatments alone.
A new study shows that stereotactic ablative radiotherapy (SABR) is as safe and effective for patients with one kidney as it is for those with two. The treatment provided high local control and cancer-specific survival rates, with minimal impact on renal function.
A study by NRG Oncology found that short-term androgen-deprivation therapy (ADT) combined with radiotherapy improved overall survival for men with early stage prostate adenocarcinoma for up to 10.4 years. However, the benefits dissipated after 18 years.
A phase III trial has established the radiation/cisplatin combination as the standard of care for human papillomavirus (HPV)-related oral cancers, resulting in higher overall and progression-free survival rates compared to cetuximab/radiation. The treatment also showed a lower rate of serious side effects, particularly with cisplatin.
A large, long-term study found SBRT to be safe and effective for men with low- and intermediate-risk prostate cancer. The treatment delivered substantially larger doses of radiation per session, reducing the duration of treatment without increasing the risk of severe side effects.
Researchers found a link between higher levels of interleukin-10 (IL-10) and lower disease-free survival rates after radiotherapy. Elevated CRP levels, a marker of inflammation, were not associated with DFS.
A large comparison study found that radiotherapy to the prostate improved failure-free survival but not overall survival in men with newly diagnosed metastatic prostate cancer and a low burden of disease. The treatment was well-tolerated, with only modest side effects.
A new study from the University of Pennsylvania found that cancer patients can safely use topical skin treatments during radiation therapy without increasing the radiation dose to their skin. The study challenged common advice given to patients and debunked the myth that these treatments increase radiation damage.
Researchers at Ohio State University Wexner Medical Center found that papaverine inhibits mitochondrial respiration and sensitizes model tumors to radiation. The study suggests that modifying the papaverine molecule could lead to a new class of radiosensitizing drugs with fewer side effects.
Researchers found that stereotactic radiation therapy doubles progression-free survival and increases overall survival by a median of 13 months in patients with limited metastatic cancer. The treatment also improved survival rates, but with increased side effects.
The new guideline recommends moderate hypofractionation (240-340 cGy) as an alternative to conventional fractionation for men with early-stage prostate cancer. Hypofractionated radiation therapy can be completed in four to five weeks, compared to eight to nine weeks for conventional radiation.
At ASTRO's Annual Meeting, leading researchers will present their groundbreaking findings on clinical trials and radiation oncology research. The meeting features three news briefings highlighting advances in breast, lung, genitourinary, oral, and oligometastatic cancers.
A recent study published in the journal Cancer found that patients with locally advanced prostate cancer who received a combination of prostate removal and radiation therapy had a higher rate of survival compared to those treated with radiation alone. The study analyzed data from over 13,000 men diagnosed with high-risk prostate cancer...
Researchers found that papaverine reduces tumor oxygen consumption and hypoxia in mouse models, making tumors more sensitive to radiation. This suggests repurposing papaverine to enhance radiation therapy effectiveness.
Researchers have found that disrupting the non-canonical NF-κB pathway improves the effects of radiotherapy by enhancing the immune system's ability to interact with radiation. This new approach may lead to novel combination strategies for improving cancer treatment.
Researchers studied the correlation between radiation therapy dosage to the hypothalamus and pituitary gland and development of endocrine dysfunction in pediatric and young adult patients. The study found a strong association between radiation dose and age on the development of hormone deficiencies, supporting the benefits of advanced ...
Researchers have developed a new drug, GC4419, that appears to prevent severe oral mucositis (SOM), a painful side effect of radiation therapy for head and neck cancers. The drug has already been designated as a breakthrough therapy by the FDA and shows safety and efficacy in clinical trials.
Researchers developed an AI tool to automate radiation therapy planning, reducing treatment development time from days to hours. The software achieves comparable results to conventional methods and has the potential to improve patient care and outcomes.
A new study published in European Urology found that high-intensity focused ultrasound (HIFU) treatment is as effective as surgery or radiotherapy in treating prostate cancer, with lower risks of side effects. After five years, the cancer survival rate from HIFU was 100%, comparable to surgery and radiotherapy.
Researchers found that irradiating chest lymph nodes in patients with early stage breast cancer improved overall survival by 2.4% compared to treating only the breast/thoracic wall. The study involved 4004 patients and showed no increase in non-breast cancer related mortality or serious complications.
Weichselbaum, Professor and Chairman of Radiation and Cellular Oncology at the University of Chicago, has made significant contributions to understanding oligometastasis. His work on curing tumors through surgery or radiation therapy has been supported by several studies demonstrating successful treatments.
Researchers found that d-limonene, a compound in citrus oils, protected cells producing saliva in mice exposed to radiation therapy. The study shows promising results for alleviating dry mouth in head and neck cancer patients.
Researchers discovered a new strategy against anaplastic thyroid cancer using stereotactic body radiation therapy (SBRT), which showed better results than conventional radiotherapy. The study was made possible by a patient's donation of $10,000 to fund research.
Researchers aim to identify genetic markers that can predict tumor response to radiation therapy, leading to more personalized treatment approaches. The goal is to improve treatment responses, reduce toxicity, and enhance quality of life for cancer survivors.
A new AI method developed by MD Anderson researchers uses deep neural networks to automate the contouring of high-risk clinical target volumes in head and neck cancers. The model achieves comparable results to trained oncologists, offering a potential solution to reduce inter-physician variability and improve treatment efficiency.
Research finds that accelerated partial breast irradiation is as effective as whole breast radiotherapy in improving quality of life. Women treated with targeted therapy experienced reduced symptoms and better quality of life compared to those receiving standard treatment.
Researchers found that ultrahypofractionated radiotherapy is just as effective as standard radiotherapy in stopping prostate cancer from returning, with no significant long-term side effects. Patients treated with this method spend less time traveling to and from hospital for treatment.
Research suggests that tiny differences in patient position during radiotherapy can lead to reduced survival chances, particularly when tumours are close to vital organs like the heart. Tightening treatment guidelines could improve survival rates by ensuring more accurate patient positioning.
A study found that elderly patients with locally advanced lung cancer who received simultaneous radiotherapy and chemotherapy had worse survival rates compared to younger patients. In contrast, those treated with sequential chemo-radiotherapy or radiotherapy alone had similar survival rates.
The American Society for Radiation Oncology updates its clinical guideline to recommend concurrent chemotherapy for certain patients with incurable stage III non-small cell lung cancer, improving quality of life and alleviating symptoms. The new guideline also provides recommendations for delivery and dosing of radiation therapy.
A recent NRG Oncology study found that high-dose radiotherapy improves biochemical control and reduces distant metastases in men with intermediate-risk prostate cancer, but does not enhance overall survival. The treatment also resulted in more side effects compared to standard radiotherapy.